WCLC2016_Onsite Program_vF_low res

SECTION 5 IASLC andConference AwardsIASLC Distinguished Awards 50IASLC Fellowship 54Award Winners 55IASLC International 58Mentorship Award Winners 59WCLC 2016 Young 60Investigator Award Winners 60WCLC 2016 Developing 61Nation Award Winners IASLC/WCLC 2016 PatientAdvocacy Award Winners WCLC 2016 LectureshipAward Winners WCLC 2016 CommunicationsWorkshop Award Winners WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 49

IASLC DISTINGUISHED AWARDSThe IASLC Distinguished Award Winnerswill receive their awards during theOpening Ceremony 19:00 – 20:45 Roy HerbstSunday, December 4 IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD (FORMERLY IASLC SCIENTIFIC AWARD) The IASLC Scientific Award is given to an IASLC scientist for life- time scientific contributions in thoracic malignancy research and who has also contributed to the organization’s development. Dr. Herbst is Ensign Professor of Medicine, Professor of Phar- macology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT. He has led phase I development of several targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. He co-led BATTLE-1 and co-leads the BATTLE-2 clinical trial. He served as co-leader of the Devel- opmental Therapeutics Program for the YCC Support Grant. Herbst’s laboratory work focuses on immunotherapy angiogen- esis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-ac- tivated pathways. This has been translated from preclinical to clinical settings in multiple Phase II and III studies. Herbst has authored or co-authored more than 300 publications, including peer-reviewed articles, abstracts, and book chapters. His work appears in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Associ- ation of Cancer Research and chairs their Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for develop- mental therapeutics for Southwestern Oncology Group’s Lung Committee, principal investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol. In 2015, his Yale team was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant.50 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

Sumitra KeunchilThongprasert ParkIASLC MERIT AWARDThe IASLC Merit Award is given to a member of IASLC who has made an extraordinary contribution to the organization’s development.Sumitra Thongprasert is Emeritus Professor at the Faculty of Keunchil Park is Professor of the Division of Hematology-On-Medicine, Maharaj Nakorn Chiang Mai University in Chiang Mai, cology, Department of Medicine, Samsung Medical Center,Thailand. She is a director of the Center of Excellent in Cancer at Sungkyunkwan University School of Medicine, Seoul, Korea.the Bangkok Hospital Chiang Mai, Thailand. Prof. Thongprasert Prof. Park is Director of the Innovative Cancer Medicine Institute,received her undergraduate and medical degrees at Chiang Mai Samsung Medical Center.University, completing her Instructor in Medicine training in 1984.During this time she also trained in haematology/oncology at the Professor Park has served as Chair of the Scientific CommitteeMemorial Sloan-Kettering Cancer Center in New York, USA. Pro- of the Korean Cancer Association, Chair of the Lung Cancer Com-fessor Thongprasert’s main areas of interest include lung cancer mittee of the Korean Cancer Study Group(KCSG). Prof. Park alsotreatment, quality of life and targeted therapy for lung cancer served as Chairman of the Board of Directors, Korean Associationpatients. In particular she has been involved in numerous non- for Clinical Oncology (KACO) since June 2010 until May 2012. Prof.small cell lung cancer (NSCLC) studies including the FASTACT-2 Park has been also very actively involved in and served manyand IPASS trials. She is also interested in the access of treatment international activities, such as the Scientific Secretary of theand has published on cost-utility and budget impact, as well as on 12th World Conference on Lung Cancer (WCLC; Sept, 2007), andthe effect of treatment on quality of life. Professor Thongprasert the President of the 4th Asia Pacific Lung Cancer Conferencecurrently holds various positions including the Special Content (Dec, 2010). He served the IASLC as the Board of Directors sinceEditor for the Journal of Thoracic Oncology, as well as being the 2009 to 2013. Prof. Park is Co-President with Prof. Hisao Asamurapast board member of IASLC. Recently she had received the of the 18th WCLC, Oct 15-18, 2017, Yokhama, Japan. He is an Asso-ESMO Women for Oncology award from the European Society of ciate Editor for the Journal of Thoracic Oncology (JTO). Prof. ParkMedical Oncology (ESMO). She is also the Chair of the Asia-Pacific has recently joined the International Cancer Genome ConsortiumLung Cancer Conference 2016 (APLCC 2016). (ICGC) with the Korean Lung Cancer Genome Projects and is a member of the ICGC International Scientific Steering Committee since 2013. Prof. Park is the organizing Chairman of the 13th ICGC workshop to be held Jun 13-15, 2017 in Seoul, Korea. Prof. Park is the Chair of the Korea Actionable Genome Consortium (KAGC) which was launched 2016. Prof. Park’s main interests include translational researches as well as early clinical trials for the upper aero-digestive tract cancers, especially lung cancer. Recently Dr. Park is leading several early clinical trials of the targeted agents as well as many pre-clinical development programs internationally. Prof. Park has several book chapters and authored more than 300 peer-re- viewed publications in national and international journals. WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 51

IASLC DISTINGUISHED AWARDSUgo Keith KerrPastorinoJOSEPH W. CULLEN PREVENTION/ MARY J. MATTHEWS PATHOLOGY/EARLY DETECTION AWARD TRANSLATIONAL RESEARCH AWARDThe Joseph W. Cullen Award is given to an IASLC scientist for lifetime The Mary J. Matthews Award is given to an IASLC scientist for life-scientific achievements in prevention research of thoracic malignancies. time scientific achievements in pathology-translational research of thoracic malignancies.Ugo Pastorino is Director of the Thoracic Surgery Division at the Keith Kerr graduated BSc with first class honours in Pathology inIstituto Nazionale Tumori in Milan (INTM) since 2003. Graduated 1978, MB ChB in 1981, MRCPath in 1988, FRCPath in 1998 and wasin Medicine in 1979 at the University of Milan and then specialist elected Honorary FRCP(Ed) in 2006. He has been a Consultantin Emergency Surgery, Oncology and Thoracic Surgery. From Pathologist in Aberdeen since 1989. He was awarded an Honorary1980 to 1994, has been working as Thoracic Surgeon at INTM, Chair in Pulmonary Pathology by the University of Aberdeenwith several periods of study abroad. In 1994 he was appointed in 2006.as Consultant Thoracic Surgeon and honorary Senior Lecturer atthe Royal Brompton Hospital in London. From 1998 to 2002, has Throughout his career, he has worked in diagnostic histopathologybeen Director of the Thoracic Surgery Division at the European with a special interest in Thoracic Pathology, whilst keeping closeInstitute of Oncology (IEO). From 2010 to February 2014 has been links with the clinical practice of thoracic medicine, especiallyDirector of the Surgery Department and from October 2014 to thoracic oncology. He has an active research interest in his ownSeptember 2015 has been Scientific Director, at the INTM. laboratory and through national and international collaboration. He enjoys under- and postgraduate teaching.Peculiar features of surgical activity have been the innovativetechniques of minimally invasive lung resection, muscle-sparing He has had a career long interest in lung cancer. He has been athoracotomies and broncho-vascular reconstruction; trans-ma- member of IASLC for 16 years and contributed to the last 7 WCLCnubrial approach to apical chest tumors; management of T4 meetings, including as invited faculty. He is a member of the IASLCtumors with SVC and major vessel resection; volume reduction Pathology Panel. He was elected to the IASLC Board of Directorsfor concurrent emphysema; induction chemotherapy and pulmo- for four years, 2013-2017. He is a member of ESMO and serves onnary metastasectomy. the ESMO Lung Educational Faculty. He is Pathology Chair for the ETOP Lungscape group. He served on the international PulmonaryClinical research focus on diagnosis and treatment of primary Pathology Society council and is a British Thoracic Society mem-and secondary lung cancer, use of PET scan for staging of thoracic ber of more than 30 years. He was a member of the panel for themalignancies, salvage surgery of lung metastases and mediasti- 2004 and 2015 WHO lung cancer classifications. He is a member ofnal tumors, biology of lung carcinogenesis and chemoprevention the International Mesothelioma Panel, and served as Pathologyof smoking-induced cancers. In 1991 he launched the Interna- chair for the EORTC lung cancer group from 2006-2014. He hastional Registry of Lung Metastases. worked on numerous clinical research lung cancer trials groups (SLCF, NCRI, UKLS), guideline development for lung cancer diag-He has conducted clinical trials involving 20.645 patients/subjects: nosis and management (RCPath, SIGN, NICE, BTS, ESMO, IASLC/ ETOP, IASLC/CAP/AMP), Conference scientific committees (ELCC,• 6 randomized clinical trials of 4.029 patients; ESMO, BTOG) and other lung cancer organization committees• 8 non randomized clinical trials of 8.273 patients; (UKLCC, BTOG). He is currently involved in the revision of the BTS• 1 randomized clinical trial of 4.099 high risk subjects; Mesothelioma guidelines and is a panel member for the revision of• 5 non randomized clinical trials of 5035 high risk subjects. the CAP/IASLC/AMP guidelines for molecular pathology testing in lung cancer.He is the principal investigator of three on-going prospectivetrials on lung cancer screening with LDCT and circulating miRNAs. He is a regular invited speaker and faculty member at major inter- national Conferences, both in Pathology and in Thoracic Oncology.Author of 319 papers on Journals with Impact Factor (IF 1221,408 – He is an Associate Editor for the Journal of Thoracic Oncology.IFm 508,616). The H-index is 47.52 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

PREVIOUS IASLC DISTINGUISHED AWARD WINNERSPREVIOUS DISTINGUISHED IASLC AWARD WINNERSYEAR IASLC MERIT IASLC MARY J. MATTHEWS IASLC JOSEPH W. CULLEN IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD AWARD PATHOLOGY/TRANSLATIONAL PREVENTION/EARLY (FORMERLY IASLC SCIENTIFIC AWARD) RESEARCH AWARD DETECTION AWARD Robert Ginsberg John D. Minna1991 Clifton Mountain Daniel C. Ihde Thierry LeChevalier1994 Y. Shimosato/ Geno Saccamanno Jesse Steinfeld Frances Shepherd N. Bleehen Bruce E. Johnson/ Thomas Lynch Nagahiro Saijo1997 Heine H. Hansen William Travis Clifford Douglas David R. Gandara Yi-Long Wu2000 Desmond Carney Yokio Shimosato 2003 Paul A. Bunn, Jr. Adi Gazdar Paul van Houtte 2005 Harubumi Kato Elisabeth Brambilla Nigel Gray 2007 Peter Goldstraw Fred R. Hirsch James Mulshine 2009 Giorgio Scagliotti Masayuki Noguchi Stephen Lam 2011 David Ball Philip Hasleton John K. Field 2013 Jim Jett Tetsuya Mitsudomi Pieter E. Postmus 2015 Harvey Pass Ming Tsao Jacek Jassem WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 53

IASLC FELLOWSHIP AWARD WINNERS2016 – 2017 2015 – 2016ESRA AKBAY MARK M. AWADUT Southwestern Medical Center, Dallas, Texas, USA Harvard Medical School & the Dana-Farber Cancer Institute, Boston, Massachusetts, USAVALSAMO ANAGNOSTOUSidney Kimmel Comprehensive Cancer Center at Johns Hopkins PUEY LING CHIAUniversity, Baltimore, Maryland, USA Olivia Newton-John Cancer Research Institute, Austin Health, Victoria, AustraliaLUIZ HENRIQUE ARAUJOBrazilian National Cancer Institute , INCA, Brazil JILL LARSEN QIMR Berghofer Medical Research Institute,PUEY LING CHIA Brisbane, AustraliaOlivia Newton-John Cancer Research Institute,Austin Health, Victoria, Australia COLIN LINDSAY Institut Gustave-Roussy, Paris, FranceSIDDHARTHA DEVARAKONDAWashington University School of Medicine, YOICHIRO MITSUISHISt. Louis, Michigan, USA Dana-Farber Cancer Institute, Boston, Massachusetts, USAJULIE GEORGE SARA PILOTTODepartment of Translational Genomics, University of Verona, G.B. Rossi Academic Hospital, Verona, ItalyUniversity of Cologne, Cologne, GermanyROBIN MJELLE ADRIAN G. SACHERDepartment of Cancer Research and Molecular Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts, USANorwegian University of Science and Technology NTNU, Norway KENICHI SUDANICOLAS REYNOIRD Kinki University Faculty of Medicine, Osaka-Sayama, JapanInstitute Albert Bonnoit, Centre Recherche INSERM U1209 - CNRS -UGA, Grenoble, France APICHAT TANTRAWORASIN Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandAPICHAT TANTRAWORASINDepartment of Thoracic Surgery, SILVESTRE VICENTIcahn School of Medicine at Mount Sinai, New York, USA Center for Applied Medical Research (CIMA), Pamplona, Spain2014 – 2016: IASLC – APLCC 2014 – 2016PIYADA SITTHIDEATPHALBOON YAYI HEChulalongkorn University and King Chulalongkorn Memorial Shanghai Pulmonary Hospital, Tongji University, Shanghai, ChinaHospital, Bangkok, Thailand54 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG





















Exhibit Hall open and Posters on displayTUESDAY WEDNESDAYDECEMBER 6, 2016 DECEMBER 7, 2016 (09:30–16:30)Meet the Expert Science Highlights Opposed Industry Meet the Expert Science Highlights Opposed Industry 07:30 Exhibit Hall open and Posters on displaySessionsSessionsSymposiaSessionsSessionsSymposia 08:00 08:30 (09:30–16:30)Ticketed Sessions(07:30–08:30)(07:30–08:30)Ticketed Sessions(07:30–08:30)(07:30–08:30)09:00 (07:30–08:30) (07:30–08:30) 09:30 PROGRAM AT A GLANCE10:00 Presidential Symposium Plenary Session: Immune Checkpoint 10:30 Inhibitors in Advanced NSCLC 11:00 (08:35–10:25) 11:30 (08:45–09:40) 12:00 12:30 Plenary Keynote Lecture (09:45–10:15) 13:00 13:30Poster Presenters Present Press Conference Poster Presenters Present Press Conference 14:00 (10:25–11:00) (10:30–11:45) (10:25–11:00) (10:30–11:45) 14:30 15:00Educational, Science, Educational, Science, 15:30 Oral and Mini Oral Oral and Mini Oral 16:00 Sessions Sessions 16:30 17:00 (11:00–12:30) (11:00–12:30) 17:30 18:00Industry Supported Symposium Industry Supported Symposium 18:30 supported by Novarits supported by MSD Oncology 19:00 19:30 (12:45–14:15) (12:45–14:15) 20:00 20:30 Poster Educational, IASLC Bus. Meeting Poster Presenters Educational, Science, 21:00Presenters Science, Oral (14:30–15:00) Present Oral and Mini Oral 21:30 and Mini Oral Sessions 22:00 Present (14:30–15:45) 22:30 Sessions (14:20–15:50) 23:00(14:30–15:45) (14:20–15:50) Educational, Science, Closing Plenary Session Oral and Mini Oral Sessions (16:00–18:00) (16:00–17:30)Industry Supported Symposium supported by Roche (17:45–19:15) WCLC 2016 Together against Lung Cancer Ticketed Event (19:00–23:00) WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 65

SESSIONS AT A GLANCE  BY DAY ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSIONSESSIONS AT A GLANCE  BY DAY TRACK # SESSION TITLE DATE START END ROOM SATURDAY, DECEMBER 3, 2016 WS01 Young Investigator Research and Communication Training Saturday, 08:00 17:00 Schubert 1-4 (By invitation only) Dec. 3 09:00 18:00 Strauss 1 Saturday, 14:00 16:00 Strauss 2 RADIOLOGY/ WS02 IASLC Supporting the Implementation of Global CT Screening Dec. 3 STAGING/SCREENING Saturday, Dec. 3 Policy Dialogue: Tobacco Control in Central Europe: Status - Goals - Challenges SUNDAY, DECEMBER 4, 2016 RADIOLOGY/ WS03 IASLC meets ESTI: Imaging in Lung Cancer Staging and Diagnosis Sunday, 08:00 11:45 Strauss 2 STAGING/SCREENING JCES01 Joint IASLC - Chinese Society for Clinical Oncology Dec. 4 08:00 11:45 Stolz 1 - Chinese Alliance Against Lung Cancer Session (Sign up required) Sunday, 08:00 11:45 Hall C8 MESOTHELIOMA/ YI01 Clinical Trials & Scientific Mentoring Dec. 4 THYMIC Sunday, MALIGNANCIES/ Dec. 4 ESOPHAGEAL CANCER/OTHER WS04 Mesothelioma Workshop Sunday, 08:00 11:00 Stolz 2 THORACIC (Ticketed Session) Dec. 4 MALIGNANCIES NURSES WS05 International Society of Nurses in Cancer Care (ISNCC) Sunday, 08:00 12:00 Schubert 4 WS06 & BMS Foundation Collaborative Workshop (Sign up required) Dec. 4 NURSES ISS01 WS07 Management of Lung Cancer Patients Through Innovative Sunday, 08:00 12:30 Strauss 1 ISS02 Laboratory Testing Across the Clinical Continuum Workshop Dec. 4 ISS03 (Sign up required) ISS04 PL01 Current and Emerging Treatments for Patients with ALK+ NSCLC Sunday, 12:00 13:30 Strauss 3 - ARIAD Pharmaceuticals Inc. Dec. 4 International Thoracic Oncology Nursing Forum (ITONF) and Sunday, 13:30 18:30 Schubert 2 Mesothelioma Satellite Workshop: Innovating Lung Cancer Dec. 4 and Mesothelioma Care (Ticketed Session) ALK and ROS1 in NSCLC: Optimising the Continuum of Care Sunday, 13:45 15:15 Lehar 3-4 - Pfizer Oncology Dec. 4 Non-Small Cell Lung Cancer: The Programmed Death-Ligand Sunday, 15:30 17:00 Hall C2 1 (PD-L1) Receptor as a Target for Monotherapy and in Dec. 4 Combination - Merck-Pfizer Alliance Treatment Selection Strategies in Advanced NSCLC - A Symphony Sunday, 17:15 18:45 Hall C1 of Views - Eli Lilly and Company Dec. 4 19:00 20:45 Hall D (Plenary Hall) Opening Plenary Session Sunday, Dec. 4 66 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

TRACK # SESSION TITLE DATE START END ROOMMONDAY, DECEMBER 5, 2016EPIDEMIOLOGY/ SH01 WCLC 2016 Scientific Highlights Monday, 07:30 08:30 Hall C1TOBACCO CONTROL SH02 WCLC 2016 Scientific Highlights Dec. 5AND CESSATION/ MTE01 Strategies to Improve Tobacco Control in Central European 07:30 08:30 Hall C7PREVENTION, Countries (Ticketed Session) Monday,BIOLOGY/PATHOLOGY Dec. 5 07:30 08:30 Schubert 1 Monday,SCLC/ Dec. 5NEUROENDOCRINE Monday,TUMORS Dec. 5 Monday,EPIDEMIOLOGY/ Dec. 5TOBACCO CONTROL Monday,AND CESSATION/ Dec. 5PREVENTION Monday, Dec. 5BIOLOGY/PATHOLOGY MTE02 Advances in Pathology (Ticketed Session) Monday, 07:30 08:30 Schubert 2 SESSIONS AT A GLANCE  BY DAY Dec. 5 07:30 08:30 Schubert 4BIOLOGY/PATHOLOGY MTE03 Basics of Molecular Biology for the Clinician (Ticketed Session) Monday, 07:30 08:30 Schubert 5 Dec. 5 07:30 08:30 Schubert 6RADIOLOGY/ MTE04 Screening for Lung Cancer (Ticketed Session) 07:30 08:30 Strauss 3STAGING/SCREENING Monday, Dec. 5SURGERY MTE05 Where is the Place of Surgery for N2 Disease? (Ticketed Session) Monday,RADIOTHERAPY MTE06 Radiotherapy Techniques in Lung Cancer (Ticketed Session) Dec. 5 Monday,ADVANCED NSCLC, MTE07 Treatment of Elderly Patients with Lung Cancer Dec. 5 07:30 08:30 Lehar 1-2CHEMOTHERAPY/ (Ticketed Session) Monday,TARGETED THERAPY/ MTE08 Dec. 5 07:30 08:30 Lehar 3-4IMMUNOTHERAPY Immunotherapy in Early and Locally Advanced NSCLC: Monday, MTE09 Challenges and Perspectives (Ticketed Session) Dec. 5 07:30 08:30 Stolz 1EARLY STAGE ISS05 Monday, 07:30NSCLC, LOCALLY ISS06 Biomarkers for Targeted Therapies and Immune Checkpoint Dec. 5 07:30 08:30 Strauss 2ADVANCED NSCLC, WS08 Inhibitors in Advanced NSCLC (Ticketed Session) 07:30CHEMOTHERAPY/ PL02 Orchestrating Progress for Patients with Squamous Cell Lung Monday, 08:45 08:30 Stolz 2TARGETED THERAPY/ ED01 Cancer - Eli Lilly and Company Dec. 5IMMUNOTHERAPY The Changing Treatment Paradigm After Progression in Monday, 08:30 Strauss 1 Advanced EGFR-Mutated NSCLC - PeerVoice Dec. 5CHEMOTHERAPY/ Special Session: CAP/IASLC/AMP Guidelines for Molecular Monday, 10:20 Hall DTARGETED THERAPY/ Testing in Lung Cancer Dec. 5 (Plenary Hall)IMMUNOTHERAPY Distinguished Lecture & Plenary Session: Tobacco Control Monday, Dec. 5 11:00 12:30 Hall C1EPIDEMIOLOGY/ Biology of Lung Cancer Monday,TOBACCO CONTROL Dec. 5AND CESSATION/ Monday,PREVENTION Dec. 5 Monday,BIOLOGY/PATHOLOGY, Dec. 5CHEMOTHERAPY/ Monday,TARGETED THERAPY/ Dec. 5IMMUNOTHERAPY Monday, Dec. 5PALLIATIVE CARE/ ED02 Palliative Care in Lung Cancer: A Global Challenge 11:00 12:30 Strauss 3ETHICS Monday, 11:00 12:30 Lehar 3-4 Dec. 5RADIOLOGY/ SC01 Staging Before and After Induction Therapy for N2 Disease 11:00 12:30 Strauss 1STAGING/SCREENING, SC02 Multifocal Lung Cancer 11:00 12:30 Strauss 2LOCALLY ADVANCED 11:00NSCLC 11:00 11:00RADIOLOGY/ 11:00STAGING/SCREENING,PULMONOLOGYRADIOTHERAPY SC03 Advances in Radiation OncologyCHEMOTHERAPY/ SC04 EGFR Tyrosine Kinase Inhibitors: 12:30 Hall C7TARGETED THERAPY/ SC05 A Model for Successful Drug DevelopmentIMMUNOTHERAPY IA01 Novel Drugs in Thoracic Cancers 12:30 Hall C2 IA02 Multidisciplinary Diagnosis of Lung Cancer in the Era ofCHEMOTHERAPY/ Molecular Medicine 12:30 Stolz 1TARGETED THERAPY/ NU01 Interactive Session Staging Group I (Ticketed Session) 12:30 Schubert 3IMMUNOTHERAPY Prevention 11:00 12:30 Schubert 5BIOLOGY/PATHOLOGYRADIOLOGY/STAGING/SCREENINGNURSES,EPIDEMIOLOGY/TOBACCO CONTROLAND CESSATION/PREVENTION WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 67

ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION TRACK # SESSION TITLE DATE START END ROOM Monday, PATIENT SUPPORT PA01 Lung Cancer Diagnosis and Care: Dec. 5 11:00 12:30 Schubert 6 AND ADVOCACY Identifying and Improving Community Standards Monday, GROUPS Dec. 5 SURGERY OA01 Risk Assessment and Follow up in Surgical Patients Monday, 11:00 12:30 Schubert 2 Dec. 5SESSIONS AT A GLANCE  BY DAY MESOTHELIOMA/ OA02 Novel Targets and Biomarkers in Malignant Pleural 11:00 12:30 Stolz 2 THYMIC Mesothelioma Monday, MALIGNANCIES/ Dec. 5 ESOPHAGEAL OA03 Immunotherapy Checkpoint Inhibitors in Advanced NSCLC Monday, 11:00 12:30 Hall C8 CANCER/OTHER Dec. 5 THORACIC OA04 Epidemiology and Prevention of Lung Cancer Monday, 11:00 12:30 Schubert 4 MALIGNANCIES Dec. 5 MA01 Improvement and Implementation of Lung Cancer Screening Monday, 11:00 12:30 Lehar 1-2 CHEMOTHERAPY/ Dec. 5 12:45 14:15 Hall D TARGETED THERAPY/ ISS07 Immuno-Oncology and Lung Cancer: Emerging Data and Recent Monday, 14:20 15:50 (Plenary Hall) IMMUNOTHERAPY Developments - Bristol-Myers Squibb Dec. 5 14:20 Strauss 2 Monday, 14:20 EPIDEMIOLOGY/ OA05 Treatment Advances in SCLC Dec. 5 14:20 TOBACCO CONTROL Monday, AND CESSATION/ Dec. 5 14:20 PREVENTION Monday, Dec. 5 RADIOLOGY/ Monday, STAGING/SCREENING Dec. 5 SCLC/ Monday, NEUROENDOCRINE Dec. 5 TUMORS Monday, Dec. 5 BIOLOGY/PATHOLOGY OA06 Prognostic & Predictive Biomarkers Monday, 15:50 Strauss 1 Dec. 5 SURGERY OA07 Lymph Node Metastases and Other Prognostic Factors Monday, 15:50 Stolz 1 for Local Spread Dec. 5 Monday, BIOLOGY/PATHOLOGY MA02 RNA in Lung Cancer Dec. 5 15:50 Stolz 2 EPIDEMIOLOGY/ MA03 Epidemiology, Risk Factors and Screening Monday, 15:50 Lehar 3-4 TOBACCO CONTROL ED03 Global Tobacco Control Policies: Advances & Challenges Dec. 5 AND CESSATION/ ED04 Bronchopulmonary Carcinoids 14:30 15:45 Hall C1 PREVENTION Monday, Dec. 5 14:30 15:45 Lehar 1-2 EPIDEMIOLOGY/ Monday, 14:30 TOBACCO CONTROL Dec. 5 14:30 AND CESSATION/ Monday, 14:30 PREVENTION Dec. 5 Monday, SCLC/ Dec. 5 NEUROENDOCRINE TUMORS JTO Meet the JTO Editor 15:15 Schubert 4 PATIENT SUPPORT IA03 What are the Lung Cancer Patients Needs in the Different 15:45 Schubert 2 AND ADVOCACY Countries? GROUPS PC01 Invasive Mediastinal Staging for N2 Disease 15:45 Hall C2 RADIOLOGY/ STAGING/SCREENING SC06 Novel Therapies in Malignant Pleural Mesothelioma 14:30 15:45 Strauss 3 and Thymic Malignancies MESOTHELIOMA/ THYMIC ED05 The 8th Edition of the TNM Staging System 16:00 17:30 Hall C1 MALIGNANCIES/ 16:00 17:30 Stolz 1 ESOPHAGEAL 16:00 CANCER/OTHER 16:00 THORACIC MALIGNANCIES RADIOLOGY/ STAGING/SCREENING PALLIATIVE CARE/ ED06 Symptom Management in Lung Cancer 17:30 Stolz 2 ETHICS SC07 New Challenges for Lung Cancer: Waterpipes and E-Cigarettes SC08 IASLC- ESTS Joint Symposium: The Borderline Patient 17:30 Hall C7 EPIDEMIOLOGY/ TOBACCO CONTROL AND CESSATION/ PREVENTION PULMONOLOGY, SURGERY 68 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

TRACK # SESSION TITLE DATE START END ROOM SC09 Radiotherapy for a Global CancerRADIOTHERAPY, Monday, 16:00 17:30 Hall C8REGIONAL ASPECTS/ Dec. 5HEALTH POLICY/ SC10 Squamous Cell NSCLC 16:00 17:30 Strauss 3PUBLIC HEALTH Monday, SC11 ALK, ROS1 and Rare Mutations in NSCLC Dec. 5 16:00 17:30 Lehar 1-2ADVANCED NSCLC, 16:00CHEMOTHERAPY/ SC12 Anticancer Drug Development in the 21st Century Monday, 16:00 17:30 Hall C2TARGETED THERAPY/ Dec. 5 16:00IMMUNOTHERAPY IA04 Interactive Session Target Delineation: Group I Monday, 16:00 17:30 Schubert 3 SESSIONS AT A GLANCE  BY DAY (Ticketed Session) Dec. 5 16:00CHEMOTHERAPY/ Monday, 16:00TARGETED THERAPY/ NU02 Preparing Patients for Treatment Dec. 5 16:00 17:30 Schubert 5IMMUNOTHERAPY Monday, 16:00 PA02 Access to Care - Equal Chances in the World? Dec. 5 17:30 Schubert 6CHEMOTHERAPY/ Monday,TARGETED THERAPY/ OA08 Targeted Therapies in Brain Metastases Dec. 5 17:30 Schubert 1IMMUNOTHERAPY Monday, 17:30 Lehar 3-4 Dec. 5 17:30 Strauss 1RADIOTHERAPY Monday, 17:30 Strauss 2 Dec. 5NURSES Monday, Dec. 5PATIENT SUPPORT Monday,AND ADVOCACY Dec. 5GROUPS Monday,ADVANCED NSCLC Dec. 5ADVANCED NSCLC MA04 HER2, P53, KRAS and Other Targets in Advanced NSCLCPULMONOLOGY MA05 Innovative Techniques in Pulmonology and the Impact MA06 on Lung CancerLOCALLY ADVANCED Locally Advanced NSCLC: Risk Groups, Biological FactorsNSCLC ISS08 and Treatment Choices Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus in EGFR-Targeted Therapy 17:45 19:15 Hall C7 - A prIME Oncology Satellite Symposium Supported by Boehringer Ingelheim Pharma GmbH & Co. KG.TUESDAY, DECEMBER 6, 2016EARLY STAGE NSCLC, SH03 WCLC 2016 Scientific Highlights Tuesday, 07:30 08:30 Hall C1LOCALLY ADVANCED SH04 Dec. 6 07:30 08:30 Hall C7NSCLC, SURGERY MTE10 WCLC 2016 Scientific Highlights Tuesday, 07:30 08:30 Schubert 1 MTE11 Unique Biologic Aspects of Tobacco-Induced Lung Cancer Dec. 6 07:30 08:30 Schubert 2RADIOLOGY/ MTE12 (Ticketed Session) Tuesday, 07:30 08:30 Schubert 4STAGING/SCREENING, MTE13 The Clinical Impact of the 2015 WHO Classification Dec. 6 07:30 08:30 Schubert 5PULMONOLOGY MTE14 of Lung Tumors (Ticketed Session) Tuesday, 07:30 08:30 Schubert 6 MTE15 Clinically Relevant Signal Transduction Pathways Dec. 6 07:30 08:30 Strauss 1BIOLOGY/PATHOLOGY MTE16 (Ticketed Session) Tuesday, 07:30 08:30 Strauss 2 MTE17 Dec. 6 07:30 08:30 Strauss 3BIOLOGY/PATHOLOGY MTE18 Basic Immunology for the Clinician (Ticketed Session) Tuesday, 07:30 08:30 Lehar 1-2 Dec. 6BIOLOGY/PATHOLOGY MTE19 How to Implement Screening/Early Detection Tuesday, 07:30 08:30 Stolz 1 in Routine Practice (Ticketed Session) Dec. 6BIOLOGY/PATHOLOGY, MTE20 Lymph Node Mapping in Lung Cancer (Ticketed Session) Tuesday, 07:30 08:30 Stolz 2CHEMOTHERAPY/ Precision Medicine in NSCLC: Lessons Learned and Perspectives Dec. 6TARGETED THERAPY/ (Ticketed Session) Tuesday,IMMUNOTHERAPY Maintenance Therapy Versus Early Second-Line Therapy Dec. 6 in Advanced NSCLC (Ticketed Session) Tuesday,RADIOLOGY/ Perspectives in the Systemic Treatment of Small-Cell Dec. 6STAGING/SCREENING Lung Cancer (Ticketed Session) Tuesday, Dec. 6RADIOLOGY/ Monitoring of Treatment Outcome in Clinical TrialsSTAGING/SCREENING, and in Routine Practice (Ticketed Session) Tuesday,SURGERY Radiotherapy of Locally Advance NCSLC: Dec. 6 Selecting the Right Patient for the Right RadiotherapyCHEMOTHERAPY/ (Ticketed Session) Tuesday,TARGETED THERAPY/ Dec. 6IMMUNOTHERAPYADVANCED NSCLC,CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPYSCLC/NEUROENDOCRINETUMORSCHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY,TRIAL DESIGN/STATISTICSRADIOTHERAPY WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 69

ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION TRACK # SESSION TITLE DATE START END ROOM ISS09 Targeted Therapy on the Horizon for SCLC - AbbVie Tuesday, 07:30 08:30 Lehar 3-4 PL03 Presidential Symposium Dec. 6 08:35 10:25 Hall D ED07 Classification and Druggable Targets of Thoracic Tumors Tuesday, (Plenary Hall)SESSIONS AT A GLANCE  BY DAY Dec. 6 BIOLOGY/PATHOLOGY, SC13 11:00 12:30 Hall C1 CHEMOTHERAPY/ SC14 Tuesday, TARGETED THERAPY/ SC15 Dec. 6 IMMUNOTHERAPY IA05 RADIOLOGY/ IA06 Interaction of COPD and Lung Cancer - Consequences for Early Tuesday, 11:00 12:30 Stolz 1 STAGING/SCREENING, NU03 Diagnosis and Management Dec. 6 11:00 PULMONOLOGY PA03 11:00 CHEMOTHERAPY/ OA09 Immunotherapy of NSCLC Tuesday, 11:00 12:30 Hall C2 TARGETED THERAPY/ OA10 Clinical Trials: How to Set Priorities? Dec. 6 11:00 IMMUNOTHERAPY OA11 The Practical use of the TNM Classifications for Thoracic Cancers Tuesday, 11:00 12:30 Hall C8 OA12 Interactive Session Staging Group II (Ticketed Session) Dec. 6 11:00 TRIAL DESIGN/ MA07 Supporting Patients Receiving Treatment Tuesday, 11:00 12:30 Hall C7 STATISTICS MA08 Patient Support and Involvement in Research Dec. 6 11:00 ISS10 Locally Advanced NSCLC: Innovative Treatment Strategies Tuesday, 11:00 12:30 Schubert 3 RADIOLOGY/ EGFR Mutations Dec. 6 11:00 STAGING/SCREENING OA13 Angiogenesis in Advanced Lung Cancer Tuesday, 11:00 12:30 Schubert 5 SBRT and Other Issues in Early Stage NSCLC Dec. 6 11:00 RADIOLOGY/ MA09 ALK-ROS1 in Advanced NSCLC Tuesday, 12:45 12:30 Schubert 6 STAGING/SCREENING MA10 Treatment Monitoring in Advanced NSCLC Dec. 6 MA11 Novel First-Line Treatment Strategies for ALK+ NSCLC: From Tuesday, 12:30 Strauss 3 NURSES MA12 Evidence to Practice - Novartis Dec. 6 ED08 Tuesday, 12:30 Strauss 1 PATIENT SUPPORT ED09 Dec. 6 AND ADVOCACY SC16 Tuesday, 12:30 Stolz 2 GROUPS Dec. 6 Tuesday, 12:30 Strauss 2 LOCALLY ADVANCED Dec. 6 NSCLC Tuesday, 12:30 Lehar 1-2 Dec. 6 BIOLOGY/PATHOLOGY Tuesday, 12:30 Lehar 3-4 Dec. 6 ADVANCED NSCLC Tuesday, 14:15 Lehar 3-4 Dec. 6 EARLY STAGE NSCLC Immunotherapy in Malignant Pleural Mesothelioma: Tuesday, 14:20 15:50 Stolz 1 ADVANCED NSCLC Current Status of Trials and New Approaches Dec. 6 ADVANCED NSCLC Immunotherapy Combinations Tuesday, 14:20 15:50 Strauss 2 Dec. 6 14:20 15:50 Stolz 2 MESOTHELIOMA/ 14:20 15:50 Strauss 3 THYMIC Facing the Real World: New Staging System and Response Tuesday, 14:20 15:50 Schubert 1 MALIGNANCIES/ Evaluation in Immunotherapy Dec. 6 14:30 15:50 Hall C2 ESOPHAGEAL 14:30 15:50 Hall C8 CANCER/OTHER Novel Approaches in SCLC and Neuroendocrine Tumors Tuesday, 14:30 15:50 Lehar 1-2 THORACIC Dec. 6 MALIGNANCIES CHEMOTHERAPY/ Miscellaneous Biology/Pathology Tuesday, TARGETED THERAPY/ Dec. 6 IMMUNOTHERAPY Early-Stage NSCLC: State-of-the-Art Treatment and Perspectives Tuesday, RADIOLOGY/ Advances in Lung Cancer Screening Dec. 6 STAGING/SCREENING Superior Sulcus Tumors Tuesday, Dec. 6 SCLC/ Tuesday, NEUROENDOCRINE Dec. 6 TUMORS BIOLOGY/PATHOLOGY EARLY STAGE NSCLC RADIOLOGY/ STAGING/SCREENING RADIOLOGY/ STAGING/SCREENING 70 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

TRACK # SESSION TITLE DATE START END ROOMREGIONAL ASPECTS/ SC17 Lung Cancer: A Global Cancer with Different Regional Challenges Tuesday, 14:20 15:50 Strauss 1HEALTH POLICY/ PC02 Dec. 6PUBLIC HEALTH NU04 PA04 By 2030 Chemotherapy will Remain Standard of Care for the Tuesday, 14:30 15:45 Hall C7CHEMOTHERAPY/ ED10 Majority of Patients with NSCLC Stages I-IV Dec. 6 14:30TARGETED THERAPY/ SC18 Managing Toxicity Tuesday, 15:45 Schubert 5IMMUNOTHERAPY SC19 Focus on Advocacy and Communication: Dec. 6 SC20 Joint IASLC/ Global Lung Cancer Coalition Session (GLCC) Tuesday, 14:30 15:45 Schubert 6NURSES SC21 Locally Advanced NSCLC: State-of-the-Art Treatment Dec. 6 Tuesday, 16:00 17:30 Hall C1 SESSIONS AT A GLANCE  BY DAYPATIENT SUPPORT SC22 Precision Screening for Lung Cancer Dec. 6 16:00 17:30 Lehar 1-2AND ADVOCACY SC23 Interventional Pulmonology in Diagnosis and Treatment Tuesday, 16:00 17:30 Lehar 3-4GROUPS IA07 of Thoracic Malignancies Dec. 6 16:00 17:30 Strauss 1 IA08 Small is Beautiful: Impact of Surgical Approach Tuesday,LOCALLY ADVANCED OA14 Dec. 6NSCLC OA15 Tuesday, OA16 Dec. 6RADIOLOGY/ OA17STAGING/SCREENING MA13 Predictive Biomarkers for Outcome of Systemic Therapy Tuesday, 16:00 17:30 Hall C7 MA14 in NSCLC Dec. 6PULMONOLOGY ISS11 Selection and Monitoring of Patients for Immune Tuesday, 16:00 17:30 Hall C8SURGERY Checkpoint Inhibitors Dec. 6 16:00 The Importance of Co-Operative Groups Tuesday, 16:00 17:30 Strauss 3BIOLOGY/PATHOLOGY, Interactive Session Target Delineation: Group II Dec. 6 16:00CHEMOTHERAPY/ (Ticketed Session) Tuesday, 16:00 17:30 Schubert 3TARGETED THERAPY/ Dec. 6 16:00IMMUNOTHERAPY 16:00 Tobacco & Youth Tuesday, 16:00 17:30 Hall C2CHEMOTHERAPY/ Dec. 6 16:00TARGETED THERAPY/ 16:00IMMUNOTHERAPY Nurses in Care for Lung Cancer and in Research Tuesday, 17:45 17:30 Schubert 5 Sublobar Resections for Early Stage NSCLC Dec. 6SCIENTIFIC Tuesday, 17:30 Stolz 2CO-OPERATION/ Dec. 6RESEARCH GROUPS Improving the Quality of Lung Cancer Care - Patients Perspective Tuesday, 17:30 Schubert 6RADIOTHERAPY Dec. 6EPIDEMIOLOGY/ Aspects of Health Policies and Public Health Tuesday, 17:30 Schubert 1TOBACCO CONTROL Dec. 6AND CESSATION/PREVENTION Modern Technologies and Biological Factors in Radiotherapy Tuesday, 17:30 Stolz 1 Immunotherapy in Advanced NSCLC: Biomarkers and Costs Dec. 6NURSES Harnessing the Power of Immunotherapy and Targeted Therapy: Tuesday, 17:30 Strauss 2 Translating Evidence Into Practice - Roche Dec. 6SURGERY Tuesday, Dec. 6PATIENT SUPPORTAND ADVOCACYGROUPSREGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTHRADIOTHERAPYADVANCED NSCLC 19:15 Hall C2WEDNESDAY, DECEMBER 7, 2016ADVANCED NSCLC, SH05 WCLC 2016 Scientific Highlights Wednesday, 07:30 08:30 Hall C1CHEMOTHERAPY/ SH06 WCLC 2016 Scientific Highlights Dec. 7TARGETED THERAPY/ WS09 Special Workshop: Tobacco Free PortfoliosIMMUNOTHERAPY Wednesday, 07:30 08:30 Hall C7 Dec. 7RADIOTHERAPY,PALLIATIVE CARE/ Wednesday, 07:30 08:30 Strauss 2ETHICS, REGIONAL Dec. 7 08:30 Schubert 1ASPECTS/HEALTH 08:30 Schubert 2POLICY/PUBLICHEALTHEPIDEMIOLOGY/TOBACCO CONTROLAND CESSATION/PREVENTIONBIOLOGY/PATHOLOGY MTE21 Next Generation Sequencing (Ticketed Session) Wednesday, 07:30 Dec. 7 07:30RADIOLOGY/ MTE22 Perspectives in Lung Cancer Imaging (Ticketed Session) Wednesday,STAGING/SCREENING Dec. 7 WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 71

ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION TRACK # SESSION TITLE DATE START END ROOM BIOLOGY/PATHOLOGY, MTE23 Biomarker Characterization: Challenges and Perspectives Wednesday, 07:30 08:30 Schubert 3 CHEMOTHERAPY/ MTE24 (Ticketed Session) Dec. 7 TARGETED THERAPY/ MTE25 Immunohistochemical Assessment of Biomarkers for ImmuneSESSIONS AT A GLANCE  BY DAY IMMUNOTHERAPY MTE26 Checkpoint Inhibitors (Ticketed Session) Wednesday, 07:30 08:30 Schubert 4 MTE27 Radiotherapy in Small Cell Lung Cancer (Ticketed Session) Dec. 7 BIOLOGY/PATHOLOGY, MTE28 EGFR Targeted Therapies: Lessons Learned (Ticketed Session) CHEMOTHERAPY/ Treatment of Lung Cancer Patients with Poor Performance Wednesday, 07:30 08:30 Schubert 5 TARGETED THERAPY/ MTE29 Status (Ticketed Session) Dec. 7 08:30 Schubert 6 IMMUNOTHERAPY Implementation of Precision Medicine in Routine Practice: 08:30 Lehar 1-2 The Latin American Experience (Ticketed Session) Wednesday, 07:30 SCLC/ Dec. 7 NEUROENDOCRINE Advances in Malignant Pleural Mesothelioma TUMOR, (Ticketed Session) Wednesday, 07:30 RADIOTHERAPY Dec. 7 CHEMOTHERAPY/ Wednesday, 07:30 08:30 Lehar 3-4 TARGETED THERAPY/ Dec. 7 IMMUNOTHERAPY Wednesday, 07:30 08:30 Stolz 1 CHEMOTHERAPY/ Dec. 7 TARGETED THERAPY/ IMMUNOTHERAPY REGIONAL ASPECTS/ HEALTH POLICY/ PUBLIC HEALTH, CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY MESOTHELIOMA/ THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES SURGERY MTE30 Non-intubated Thoracic Surgery (Ticketed Session) Wednesday, 07:30 08:30 Stolz 2 Dec. 7 09:40 10:15 Hall D CHEMOTHERAPY/ PL04a Plenary Session: Immune Checkpoint Inhibitors in Wednesday, 08:35 (Plenary Hall) TARGETED THERAPY/ Advanced NSCLC Dec. 7 Hall D IMMUNOTHERAPY (Plenary Hall) PL04b Plenary Keynote Lecture Wednesday, 09:45 Dec. 7 ADVANCED NSCLC, ED11 Advanced NSCLC: State-of-the-Art Treatment Wednesday, 11:00 12:30 Hall C8 CHEMOTHERAPY/ ED12 Regional Tobacco Control Policies: Advances & Challenges Dec. 7 TARGETED THERAPY/ ED13 Treatment of Malignant Pleural Mesothelioma IMMUNOTHERAPY Wednesday, 11:00 12:30 Hall C7 Dec. 7 EPIDEMIOLOGY/ TOBACCO CONTROL Wednesday, 11:00 12:30 Hall C1 AND CESSATION/ Dec. 7 PREVENTION 12:30 Hall C2 12:30 Strauss 2 MESOTHELIOMA/ 12:30 Lehar 3-4 THYMIC 12:30 Strauss 3 MALIGNANCIES/ 12:30 Lehar 1-2 ESOPHAGEAL 12:30 Strauss 1 CANCER/OTHER THORACIC MALIGNANCIES PULMONOLOGY SC24 Management of Indeterminate Pulmonary Nodules Wednesday, 11:00 Dec. 7 11:00 SURGERY SC25 The Role of Surgeons in Multimodality Clinical Trials Wednesday, Dec. 7 BIOLOGY/PATHOLOGY, SC26 Angiogenesis Inhibition: Advances & Perspectives Wednesday, 11:00 CHEMOTHERAPY/ SC27 P53 and KRAS Mutations in NSCLC Dec. 7 TARGETED THERAPY/ SC28 Novel Clinical Trial Designs IMMUNOTHERAPY SC29 Access, Value Assessments and Affordability of Novel Therapies Wednesday, 11:00 Dec. 7 BIOLOGY/PATHOLOGY, CHEMOTHERAPY/ Wednesday, 11:00 TARGETED THERAPY/ Dec. 7 IMMUNOTHERAPY Wednesday, 11:00 TRIAL DESIGN/ Dec. 7 STATISTICS CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY, PATIENT SUPPORT AND ADVOCACY GROUPS 72 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

TRACK # SESSION TITLE DATE START END ROOMMESOTHELIOMA/ OA18 New Insights in the Treatment of Thymic Malignancies Wednesday, 11:00 12:30 Schubert 2THYMIC Dec. 7MALIGNANCIES/ OA19 Translational Research in Early Stage NSCLC 12:30 Schubert 3ESOPHAGEAL OA20 Immunotherapy and Markers Wednesday, 11:00 12:30 Stolz 2 SESSIONS AT A GLANCE  BY DAYCANCER/OTHER OA21 Palliative and Supportive Care for Lung Cancer Patients Dec. 7 11:00 12:30 Schubert 5THORACIC ISS12 Immuno-Oncology: A Renaissance in the Treatment of Lung Wednesday, 11:00 14:15 Lehar 3-4MALIGNANCIES Cancer – MSD Oncology Dec. 7 12:45 OA22 Wednesday, 15:50 Strauss 3EARLY STAGE NSCLC Novel Trials and Biomarkers in Malignant Pleural Mesothelioma Dec. 7 OA23 Wednesday, 15:50 Stolz 2BIOLOGY/PATHOLOGY OA24 EGFR Targeted Therapies in Advanced NSCLC Dec. 7 15:50 Stolz 1 MA15 Radiotherapy of Lung Cancer: Recent Developments 15:50 Schubert 1PALLIATIVE CARE/ MA16 Immunotherapy Prediction Wednesday, 14:20 15:50 Strauss 2ETHICS MA17 Novel Strategies in Targeted Therapy Dec. 7 15:50 Lehar 1-2 ED14 Genetic Drivers 15:45 Hall C2MESOTHELIOMA/ Small Cell Lung Cancer Wednesday, 14:20THYMIC ED15 Dec. 7 14:20 15:50 Hall C1MALIGNANCIES/ Thymic Malignancies: Update on Treatment Wednesday,ESOPHAGEAL SC30 Dec. 7 15:45 Hall C8CANCER/OTHER Novel Approaches and Regulation in Surgical EducationTHORACIC SC31 Together Against Lung Cancer Wednesday, 14:20 15:45 Hall C7MALIGNANCIES – A Strategy for Success in the 21st Century Dec. 7 YI02 Basics of Radio-Oncology 15:45 Strauss 1ADVANCED NSCLC NU05 Survivorship Wednesday, 14:20 15:45 Schubert 5 PL05 Closing Plenary Session: A Life in Thoracic Oncology - Dec. 7 18:00 Hall DRADIOTHERAPY Reflections from Giants on Milestones in the Treatment (Plenary Hall) Advances in Lung Cancer Wednesday, 14:20CHEMOTHERAPY/ Dec. 7TARGETED THERAPY/IMMUNOTHERAPY Wednesday, 14:30 Dec. 7CHEMOTHERAPY/TARGETED THERAPY/ Wednesday, 14:30IMMUNOTHERAPY Dec. 7BIOLOGY/PATHOLOGY Wednesday, 14:30 Dec. 7SCLC/NEUROENDOCRINE Wednesday, 14:30TUMORS Dec. 7MESOTHELIOMA/ Wednesday, 14:30THYMIC Dec. 7 14:30MALIGNANCIES/ Wednesday,ESOPHAGEAL Dec. 7CANCER/OTHERTHORACICMALIGNANCIESSURGERYREGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH,SCIENTIFICCO-OPERATION/RESEARCH GROUPSRADIOTHERAPYNURSES Wednesday, 16:00 Dec. 7 WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 73

SESSIONS AT A GLANCE  BY TRACK ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION # SESSION TITLE DATE START END ROOM ADVANCED NSCLCSESSIONS AT A GLANCE  BY TRACK MTE07 Treatment of Elderly Patients with Lung Cancer (Ticketed Session) Monday, 07:30 08:30 Lehar 1-2 Dec. 5 17:30 Lehar 3-4 17:30 Schubert 1 MA04 HER2, P53, KRAS and Other Targets in Advanced NSCLC Monday, 16:00 17:30 Strauss 3 Dec. 5 08:30 Strauss 3 12:30 Lehar 1-2 OA08 Targeted Therapies in Brain Metastases Monday, 16:00 12:30 Lehar 3-4 Dec. 5 12:30 Stolz 2 17:30 Strauss 2 SC10 Squamous Cell NSCLC Monday, 16:00 08:30 Hall C1 Dec. 5 12:30 Hall C8 15:50 Stolz 2 MTE17 Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC Tuesday, 07:30 (Ticketed Session) Dec. 6 MA06 ALK-ROS1 in Advanced NSCLC Tuesday, 11:00 Dec. 6 MA08 Treatment Monitoring in Advanced NSCLC Tuesday, 11:00 Dec. 6 OA11 Angiogenesis in Advanced Lung Cancer Tuesday, 11:00 Dec. 6 MA14 Immunotherapy in Advanced NSCLC: Biomarkers and Costs Tuesday, 16:00 Dec. 6 SH05 WCLC 2016 Scientific Highlights Wednesday, 07:30 Dec. 7 ED11 Advanced NSCLC: State-of-the-Art Treatment Wednesday, 11:00 Dec. 7 OA23 EGFR Targeted Therapies in Advanced NSCLC Wednesday, 14:20 Dec. 7 BIOLOGY/PATHOLOGY MTE02 Advances in Pathology (Ticketed Session) Monday, 07:30 08:30 Schubert 2 Dec. 5 07:30 08:30 Schubert 4 MTE03 Basics of Molecular Biology for the Clinician (Ticketed Session) Monday, 07:30 08:30 Hall C1 Dec. 5 11:00 12:30 Hall C1 SH01 WCLC 2016 Scientific Highlights Monday, 11:00 12:30 Stolz 1 Dec. 5 14:20 15:50 Stolz 2 ED01 Biology of Lung Cancer Monday, 14:20 15:50 Strauss 1 Dec. 5 07:30 08:30 Schubert 1 IA01 Multidisciplinary Diagnosis of Lung Cancer in the Era of Molecular Medicine Monday, 07:30 08:30 Schubert 2 Dec. 5 MA02 RNA in Lung Cancer Monday, Dec. 5 OA06 Prognostic & Predictive Biomarkers Monday, Dec. 5 MTE10 Unique Biologic Aspects of Tobacco-Induced Lung Cancer (Ticketed Session) Tuesday, Dec. 6 MTE11 The Clinical Impact of the 2015 WHO Classification of Lung Tumors Tuesday, (Ticketed Session) Dec. 6 74 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

# SESSION TITLE DATE START END ROOMMTE12 Clinically Relevant Signal Transduction Pathways (Ticketed Session) Tuesday, 07:30 08:30 Schubert 4MTE13 Basic Immunology for the Clinician (Ticketed Session) Dec. 6 07:30 ED07 Classification and Druggable Targets of Thoracic Tumors Tuesday, 11:00 08:30 Schubert 5 OA10 EGFR Mutations Dec. 6 11:00 MA12 Miscellaneous Biology/Pathology Tuesday, 14:20 12:30 Hall C1 SC21 Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC Dec. 6 16:00MTE21 Next Generation Sequencing (Ticketed Session) Tuesday, 07:30 12:30 Strauss 1MTE23 Biomarker Characterization: Challenges and Perspectives (Ticketed Session) Dec. 6 07:30MTE24 Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors Tuesday, 07:30 15:50 Schubert 1 OA20 Immunotherapy and Markers Dec. 6 11:00 SC26 Angiogenesis Inhibition: Advances & Perspectives Tuesday, 11:00 17:30 Hall C7 SC27 P53 and KRAS Mutations in NSCLC Dec. 6 11:00 MA17 Genetic Drivers Wednesday, 14:20 08:30 Schubert 1 Dec. 7 Wednesday, 08:30 Schubert 3 Dec. 7 Wednesday, 08:30 Schubert 4 Dec. 7 Wednesday, 12:30 Stolz 2 SESSIONS AT A GLANCE  BY TRACK Dec. 7 Wednesday, 12:30 Lehar 3-4 Dec. 7 Wednesday, 12:30 Strauss 3 Dec. 7 Wednesday, 15:50 Lehar 1-2 Dec. 7CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPYMTE07 Treatment of Elderly Patients with Lung Cancer (Ticketed Session) Monday, 07:30 08:30 Lehar 1-2 Dec. 5 07:30MTE08 Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives Monday, 07:30 08:30 Lehar 3-4MTE09 (Ticketed Session) Dec. 5 11:00 Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors Monday, 11:00 08:30 Stolz 1 in Advanced NSCLC (Ticketed Session) Dec. 5 11:00 Monday, 11:00ED01 Biology of Lung Cancer Dec. 5 16:00 12:30 Hall C1 Monday, 16:00OA03 Immunotheraphy Checkpoint Inhibitors in Advanced NSCLC Dec. 5 16:00 12:30 Hall C8 Monday, 07:30SC04 EGFR Tyrosine Kinase Inhibitors: A Model for Successful Drug Development Dec. 5 07:30 12:30 Hall C7 Monday, 07:30SC05 Novel Drugs in Thoracic Cancers Dec. 5 07:30 12:30 Hall C2 Monday, 11:00SC10 Squamous Cell NSCLC Dec. 5 11:00 17:30 Strauss 3 Monday, 14:20SC11 ALK, ROS1 and Rare Mutations in NSCLC Dec. 5 17:30 Lehar 1-2 Monday,SC12 Anticancer Drug Development in the 21st Century Dec. 5 17:30 Hall C2 Tuesday,MTE13 Basic Immunology for the Clinician (Ticketed Session) Dec. 6 08:30 Schubert 5 Tuesday,MTE16 Precision Medicine in NSCLC: Lessons Learned and Perspectives (Ticketed Session) Dec. 6 08:30 Strauss 2 Tuesday,MTE17 Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC Dec. 6 08:30 Strauss 3MTE19 (Ticketed Session) Tuesday, Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice Dec. 6 08:30 Stolz 1 (Ticketed Session) Tuesday, Dec. 6ED07 Classification and Druggable Targets of Thoracic Tumors Tuesday, 12:30 Hall C1 Dec. 6SC14 Immunotherapy of NSCLC Tuesday, 12:30 Hall C2 Dec. 6MA09 Immunotherapy Combinations 15:50 Strauss 2 WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 75

ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION # SESSION TITLE DATE START END ROOM PC02 By 2030 Chemotherapy will Remain Standard of Care for the Majority of Patients Tuesday, 14:30 15:45 Hall C7 SC21 with NSCLC Stages I-IV Dec. 6 16:00 SC22 Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC Tuesday, 16:00 17:30 Hall C7 MTE23 Selection and Monitoring of Patients for Immune Checkpoint Inhibitors Dec. 6 07:30 MTE24 Biomarker Characterization: Challenges and Perspectives (Ticketed Session) Tuesday, 07:30 17:30 Hall C8 MTE26 Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors Dec. 6 07:30 MTE27 (Ticketed Session) Wednesday, 07:30 08:30 Schubert 3 MTE28 EGFR Targeted Therapies: Lessons Learned (Ticketed Session) Dec. 7 07:30 SH05 Treatment of Lung Cancer Patients with Poor Performance Status Wednesday, 07:30 08:30 Schubert 4 PL04a (Ticketed Session) Dec. 7 08:45 ED11 Implementation of Precision Medicine in Routine Practice: Wednesday, 11:00 08:30 Schubert 6 SC26 The Latin American Experience (Ticketed Session) Dec. 7 11:00SESSIONS AT A GLANCE  BY TRACK SC27 WCLC 2016 Scientific Highlights Wednesday, 11:00 08:30 Lehar 1-2 SC29 Immune Checkpoint Inhibitors in Advanced NSCLC Dec. 7 11:00 MA15 Advanced NSCLC: State-of-the-Art Treatment Wednesday, 14:20 08:30 Lehar 3-4 MA16 Angiogenesis Inhibition: Advances & Perspectives Dec. 7 14:20 P53 and KRAS Mutations in NSCLC Wednesday, 08:30 Hall C1 Access, Value Assessments and Affordability of Novel Therapies Dec. 7 09:40 Hall D Immunotherapy Prediction Wednesday, 12:30 (Plenary Hall) Novel Strategies in Targeted Therapy Dec. 7 Hall C8 Wednesday, Dec. 7 12:30 Lehar 3-4 Wednesday, Dec. 7 12:30 Strauss 3 Wednesday, Dec. 7 12:30 Strauss 1 Wednesday, Dec. 7 15:50 Schubert 1 Wednesday, Dec. 7 15:50 Strauss 2 Wednesday, Dec. 7 EARLY STAGE NSCLC MTE08 Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives Monday, 07:30 08:30 Lehar 3-4 (Ticketed Session) Dec. 5 08:30 Hall C1 12:30 Strauss 2 SH03 WCLC 2016 Scientific Highlights Tuesday, 07:30 15:50 Hall C2 Dec. 6 12:30 Schubert 3 OA12 SBRT and Other Issues in Early Stage NSCLC Tuesday, 11:00 Dec. 6 ED08 Early-Stage NSCLC: State-of-the-Art Treatment and Perspectives Tuesday, 14:30 Dec. 6 OA19 Translational Research in Early Stage NSCLC Wednesday, 11:00 Dec. 7 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION MTE01 Strategies to Improve Tobacco Control in Central European Countries Monday, 07:30 08:30 Schubert 1 (Ticketed Session) Dec. 5 07:30 Monday, 08:45 SH01 WCLC 2016 Scientific Highlights Dec. 5 11:00 08:30 Hall C1 Monday, 10:20 Hall D PL02 Distinguished Lecture and Plenary Session: Tobacco Control Dec. 5 12:30 (Plenary Hall) Monday, Schubert 5 NU01 Prevention Dec. 5 76 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

# SESSION TITLE DATE START END ROOMOA04 Epidemiology and Prevention of Lung CancerMA03 Epidemiology, Risk Factors and Screening Monday, 11:00 12:30 Schubert 4ED03 Global Tobacco Control Policies: Advances & Challenges Dec. 5 14:20SC07 New Challenges for Lung Cancer: Waterpipes and E-Cigarettes Monday, 14:30 15:50 Lehar 3-4IA08 Tobacco & Youth Dec. 5 16:00WS09 Special Workshop: Tobacco Free Portfolios Monday, 16:00 15:45 Hall C1ED12 Regional Tobacco Control Policies: Advances & Challenges Dec. 5 07:30 Monday, 17:30 Stolz 2 Dec. 5 Tuesday, 17:30 Hall C2 Dec. 6 Wednesday, 08:30 Strauss 2 Dec. 7 Wednesday, 11:00 12:30 Hall C7 Dec. 7LOCALLY ADVANCED NSCLCMTE08 Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives Monday, 07:30 08:30 Lehar 3-4 SESSIONS AT A GLANCE  BY TRACK (Ticketed Session) Dec. 5 11:00 Monday, 14:30SC01 Staging Before and After Induction Therapy for N2 Disease Dec. 5 16:00 12:30 Lehar 3-4 Monday, 07:30PC01 Invasive Mediastinal Staging for N2 Disease Dec. 5 11:00 15:45 Hall C2MA06 Locally advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices Monday, 16:00SH03 WCLC 2016 Scientific Highlights Dec. 5 17:30 Strauss 2OA09 Locally Advanced NSCLC: Innovative Treatment Strategies Tuesday,ED10 Locally Advanced NSCLC: State-of-the-Art Treatment Dec. 6 08:30 Hall C1 Tuesday, Dec. 6 12:30 Strauss 3 Tuesday, Dec. 6 17:30 Hall C1MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIESWS04 Mesothelioma Workshop Sunday, 08:00 11:00 Stolz 2 Dec. 4 11:00OA02 Novel Targets and Biomarkers in Malignant Pleural Mesothelioma Monday, 14:30 12:30 Stolz 2 Dec. 5 14:20SC06 Novel Therapies in Malignant Pleural Mesothelioma and Thymic Malignancies Monday, 07:30 15:45 Strauss 3 Dec. 5 11:00OA13 Immunotherapy in Malignant Pleural Mesothelioma: Tuesday, 11:00 15:50 Stolz 1 Current Status of Trials and New Approaches Dec. 6 14:20 Wednesday, 14:30MTE29 Advances in Malignant Pleural Mesothelioma (Ticketed Session) Dec. 7 08:30 Stolz 1 Wednesday,ED13 Treatment of Malignant Pleural Mesothelioma Dec. 7 12:30 Hall C1 Wednesday,OA18 New Insights in the Treatment of Thymic Malignancies Dec. 7 12:30 Schubert 2 Wednesday,OA22 Novel Trials and Biomarkers in Malignant Pleural Mesothelioma Dec. 7 15:50 Strauss 3 Wednesday,ED15 Thymic Malignancies: Update on Treatment Dec. 7 15:50 Hall C1NURSESWS05 International Society of Nurses in Cancer Care (ISNCC) Sunday, 08:00 12:00 Schubert 4WS07 & BMS Foundation Collaborative Workshop (Sign up required) Dec. 4 13:30 18:30 Schubert 2 International Thoracic Oncology Nursing Forum (ITONF) and Mesothelioma Sunday, 11:00 12:30 Schubert 5 Satellite Workshop: Innovating Lung Cancer and Mesothelioma Care Dec. 4 (Ticketed Session) Monday, Dec. 5NU01 Prevention WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 77

ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION # SESSION TITLE DATE START END ROOM NU02 Preparing Patients for Treatment 17:30 Schubert 5 NU03 Supporting Patients Receiving Treatment Monday, 16:00 12:30 Schubert 5 NU04 Managing Toxicity Dec. 5 15:45 Schubert 5 OA14 Nurses in Care for Lung Cancer and in Research 17:30 Schubert 5 NU05 Survivorship Tuesday, 11:00 15:45 Schubert 5 Dec. 6 Tuesday, 14:30 Dec. 6 Tuesday, 16:00 Dec. 6 Wednesday, 14:30 Dec. 7SESSIONS AT A GLANCE  BY TRACK PALLIATIVE CARE/ETHICS Monday, 11:00 12:30 Strauss 3 Dec. 5 17:30 Stolz 1 ED02 Palliative Care in Lung Cancer: A Global Challenge 08:30 Hall C7 ED06 Symptom Management in Lung Cancer Monday, 16:00 12:30 Schubert 5 SH06 WCLC 2016 Scientific Highlights Dec. 5 OA21 Palliative and Supportive Care for Lung Cancer Patients Wednesday, 07:30 Dec. 7 Wednesday, 11:00 Dec. 7 PATIENT SUPPORT AND ADVOCACY GROUPS Monday, 11:00 12:30 Schubert 6 Dec. 5 PA01 Lung Cancer Diagnosis and Care: Identifying and Improving Community Standards IA03 What are the Lung Cancer Patients Needs in the Different Countries? Monday, 14:30 15:45 Schubert 2 Dec. 5 PA02 Access to Care - Equal Chances in the World? Monday, 16:00 17:30 Schubert 6 Dec. 5 PA03 Patient Support and Involvement in Research Tuesday, 11:00 12:30 Schubert 6 Dec. 6 PA04 Focus on Advocacy and Communication: Joint IASLC/ Global Lung Cancer Coalition Tuesday, 14:30 15:45 Schubert 6 Session (GLCC) Dec. 6 OA16 Improving the Quality of Lung Cancer Care - Patients Perspective Tuesday, 16:00 17:30 Schubert 6 Dec. 6 SC29 Access, Value Assessments and Affordability of Novel Therapies Wednesday, 11:00 12:30 Strauss 1 Dec. 7 PULMONOLOGY Monday, 11:00 12:30 Strauss 1 Dec. 5 17:30 Strauss 1 SC02 Multifocal Lung Cancer 17:30 Hall C7 08:30 Hall C7 MA05 Innovative Techniques in Pulmonology and the Impact on Lung Cancer Monday, 16:00 12:30 Stolz 1 Dec. 5 17:30 Lehar 3-4 12:30 Hall C2 SC08 IASLC- ESTS Joint Symposium: The Borderline Patient Monday, 16:00 Dec. 5 SH04 WCLC 2016 Scientific Highlights Tuesday, 07:30 Dec. 6 SC13 Interaction of COPD and Lung Cancer - Consequences for Early Diagnosis Tuesday, 11:00 and Management Dec. 6 SC19 Interventional Pulmonology in Diagnosis and Treatment of Thoracic Malignancies Tuesday, 16:00 Dec. 6 SC24 Management of Indeterminate Pulmonary Nodules Wednesday, 11:00 Dec. 7 78 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

# SESSION TITLE DATE START END ROOMRADIOLOGY/STAGING/SCREENING Saturday, 09:00 18:00 Strauss 1 Dec. 3 08:00 WS02 IASLC Supporting the Implementation of Global CT Screening Sunday, 07:30 Dec. 4 11:00WS03 IASLC meets ESTI: Imaging in Lung Cancer Staging and Diagnosis Monday, 11:00 11:45 Strauss 2 Dec. 5 11:00MTE04 Screening for Lung Cancer (Ticketed Session) Monday, 11:00 08:30 Schubert 5 Dec. 5 14:30IA02 Interactive Session Staging Group I (Ticketed Session) Monday, 16:00 12:30 Schubert 3 Dec. 5 07:30MA01 Improvement and Implementation of Lung Cancer Screening Monday, 07:30 12:30 Lehar 1-2 Dec. 5 07:30SC01 Staging Before and After Induction Therapy for N2 Disease Monday, 11:00 12:30 Lehar 3-4 Dec. 5 11:00SC02 Multifocal Lung Cancer Monday, 11:00 12:30 Strauss 1 Dec. 5 14:20PC01 Invasive Mediastinal Staging for N2 Disease Monday, 14:30 15:45 Hall C2 Dec. 5 14:30ED05 The 8th Edition of the TNM Staging System Tuesday, 16:00 17:30 Hall C1 SESSIONS AT A GLANCE  BY TRACK Dec. 6 07:30MTE14 How to Implement Screening/Early Detection in Routine Practice Tuesday, 08:30 Schubert 6 (Ticketed Session) Dec. 6 Tuesday,MTE15 Lymph Node Mapping in Lung Cancer (Ticketed Session) Dec. 6 08:30 Strauss 1 Tuesday,SH04 WCLC 2016 Scientific Highlights Dec. 6 08:30 Hall C7 Tuesday,IA05 The Practical Use of the TNM Classifications for Thoracic Cancers Dec. 6 12:30 Hall C7 Tuesday,IA06 Interactive Session Staging Group II (Ticketed Session) Dec. 6 12:30 Schubert 3 Tuesday,SC13 Interaction of COPD and Lung Cancer Dec. 6 12:30 Stolz 1MA10 - Consequences for Early Diagnosis and Management Tuesday, Facing the Real World: New Staging System and Response Dec. 6 15:50 Stolz 2 Evaluation in Immunotherapy Tuesday, Dec. 6ED09 Advances in Lung Cancer Screening Tuesday, 15:50 Hall C8 Dec. 6SC16 Superior Sulcus Tumors Wednesday, 15:50 Lehar 1-2 Dec. 7SC18 Precision Screening for Lung Cancer 17:30 Lehar 1-2MTE22 Perspectives in Lung Cancer Imaging (Ticketed Session) 08:30 Schubert 2RADIOTHERAPY Monday, 07:30 08:30 Strauss 3 Dec. 5 11:00MTE06 Radiotherapy Techniques in Lung Cancer (Ticketed Session) Monday, 16:00 Dec. 5 16:00SC03 Advances in Radiation Oncology Monday, 07:30 12:30 Strauss 2 Dec. 5 16:00IA04 Interactive Session Target Delineation: Group I (Ticketed Session) Monday, 16:00 17:30 Schubert 3 Dec. 5 07:30SC09 Radiotherapy for a Global Cancer Tuesday, 07:30 17:30 Hall C8 Dec. 6MTE20 Radiotherapy of Locally Advance NCSLC: Tuesday, 08:30 Stolz 2 Selecting the Right Patient for the Right Radiotherapy (Ticketed Session) Dec. 6 Tuesday,IA07 Interactive Session Target Delineation: Group II (Ticketed Session) Dec. 6 17:30 Schubert 3 Wednesday,MA13 Modern Technologies and Biological Factors in Radiotherapy Dec. 7 17:30 Stolz 1 Wednesday,MTE25 Radiotherapy in Small Cell Lung Cancer (Ticketed Session) Dec. 7 08:30 Schubert 5SH06 WCLC 2016 Scientific Highlights 08:30 Hall C7 WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 79

ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION # SESSION TITLE DATE START END ROOM OA24 Radiotherapy of Lung Cancer: Recent Developments 15:50 Stolz 1 YI02 Basics of Radio-Oncology Wednesday, 14:20 15:45 Strauss 1 Dec. 7 Wednesday, 14:30 Dec. 7 REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH Monday, 16:00 17:30 Hall C8 Dec. 5 SC09 Radiotherapy for a Global Cancer SC17 Lung Cancer: A Global Cancer with Different Regional Challenges Tuesday, 14:20 15:50 Strauss 1 Dec. 6SESSIONS AT A GLANCE  BY TRACK OA17 Aspects of Health Policies and Public Health Tuesday, 16:00 17:30 Schubert 1 Dec. 6 MTE28 Implementation of Precision Medicine in Routine Practice: The Latin American Wednesday, 07:30 08:30 Lehar 3-4 Experience (Ticketed Session) Dec. 7 SH06 WCLC 2016 Scientific Highlights Wednesday, 07:30 08:30 Hall C7 Dec. 7 SC31 Together Against Lung Cancer - A Strategy for Success in the 21st Century Wednesday, 14:30 15:45 Hall C7 Dec. 7 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS Tuesday, 16:00 17:30 Strauss 3 Dec. 6 SC23 The Importance of Co-Operative Groups SC31 Together Against Lung Cancer - A Strategy for Success in the 21st Century Wednesday, 14:30 15:45 Hall C7 Dec. 7 SCLC/NEUROENDOCRINE TUMORS SH02 WCLC 2016 Scientific Highlights Monday, 07:30 08:30 Hall C7 OA05 Treatment Advances in SCLC Dec. 5 14:20 ED04 Bronchopulmonary Carcinoids Monday, 14:30 15:50 Strauss 2 MTE18 Perspectives in the Systemic Treatment of Small-Cell Lung Cancer (Ticketed Session) Dec. 5 07:30 MA11 Novel Approaches in SCLC and Neuroendocrine Tumors Monday, 14:20 15:45 Lehar 1-2 MTE25 Radiotherapy in Small Cell Lung Cancer (Ticketed Session) Dec. 5 07:30 ED14 Small Cell Lung Cancer Tuesday, 14:30 08:30 Lehar 1-2 Dec. 6 Tuesday, 15:50 Strauss 3 Dec. 6 Wednesday, 08:30 Schubert 5 Dec. 7 Wednesday, 15:45 Hall C2 Dec. 7 80 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

# SESSION TITLE DATE START END ROOMSURGERY Monday, 07:30 08:30 Schubert 6 Dec. 5 11:00MTE05 Where is the Place of Surgery for N2 Disease? Monday, 14:20 12:30 Schubert 2 OA01 Risk Assessment and Follow up in Surgical Patients Dec. 5 16:00 OA07 Lymph Node Metastases and Other Prognostic Factors for Local Spread Monday, 07:30 15:50 Stolz 1 SC08 IASLC- ESTS Joint Symposium: The Borderline Patient Dec. 5 07:30MTE15 Lymph Node Mapping in Lung Cancer (Ticketed Session) Monday, 16:00 17:30 Hall C7 SH03 WCLC 2016 Scientific Highlights Dec. 5 16:00 OA15 Sublobar Resections for Early Stage NSCLC Tuesday, 07:30 08:30 Strauss 1 SC20 Small is Beautiful: Impact of Surgical Approach Dec. 6 11:00MTE30 Non-intubated Thoracic Surgery (Ticketed Session) Tuesday, 14:30 08:30 Hall C1 SC25 The Role of Surgeons in Multimodality Clinical Trials Dec. 6 SC30 Novel Approaches and Regulation in Surgical Education Tuesday, 17:30 Stolz 2 Dec. 6 Tuesday, 17:30 Strauss 1 Dec. 6 Wednesday, 08:30 Stolz 2 SESSIONS AT A GLANCE  BY TRACK Dec. 7 Wednesday, 12:30 Strauss 2 Dec. 7 Wednesday, 15:45 Hall C8 Dec. 7TRIAL DESIGN/STATISTICSMTE19 Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice Tuesday, 07:30 08:30 Stolz 1 (Ticketed Session) Dec. 6 11:00 12:30 Hall C8 Tuesday, 11:00 12:30 Lehar 1-2SC15 Clinical Trials: How to Set Priorities? Dec. 6 Wednesday,SC28 Novel Clinical Trial Designs Dec. 7INDUSTRY SUPPORTED SYMPOSIAISS01 Current and Emerging Treatments for Patients with ALK+ NSCLC - ARIAD Sunday, 12:00 13:30 Strauss 3ISS02 Pharmaceuticals Inc. Dec. 4 13:45ISS03 ALK and ROS1 in NSCLC: Sunday, 15:30 15:15 Lehar 3-4ISS04 Optimising the Continuum of Care - Pfizer Oncology Dec. 4 17:15ISS05 Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Receptor Sunday, 07:30 17:00 Hall C2ISS06 as a Target for Monotherapy and in Combination - Merck-Pfizer Alliance Dec. 4 07:30ISS07 Treatment Selection Strategies in Advanced Sunday, 12:45 18:45 Hall C1 NSCLC - A Symphony of Views - Eli Lilly and Company Dec. 4ISS08 Orchestrating Progress for Patients with Squamous Cell Lung Cancer Monday, 08:30 Strauss 2 - Eli Lilly and Company Dec. 5ISS09 The Changing Treatment Paradigm After Progression in Advanced Monday, 08:30 Stolz 2ISS10 EGFR-Mutated NSCLC - PeerVoice Dec. 5 14:15 Hall DISS11 Immuno-Oncology and Lung Cancer: Monday, (Plenary Hall)ISS12 Emerging Data and Recent Developments - Bristol-Myers Squibb Dec. 5 Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus in EGFR-Targeted Therapy - A prIME Oncology Satellite Symposium Monday, 17:45 19:15 Hall C7 Supported by Boehringer Ingelheim Pharma GmbH & Co. KG. Dec. 5 Targeted Therapy on the Horizon for SCLC - AbbVie Tuesday, 07:30 08:30 Lehar 3-4 Novel First-Line Treatment Strategies for ALK+ NSCLC: From Evidence to Practice Dec. 6 12:45 - Novartis Tuesday, 17:45 14:15 Lehar 3-4 Advances in the Treatment of NSCLC: Harnessing the Power of Immunotherapy Dec. 6 12:45 and Targeted Therapy: Translating Evidence Into Practice - Roche Tuesday, 19:15 Hall C2 Immuno-Oncology: A Renaissance in the Treatment of Lung Cancer Dec. 6 - MSD Oncology Wednesday, 14:15 Lehar 3-4 Dec. 7 WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 81

WORKSHOPS AND SPECIAL SESSIONS SATURDAY, DECEMBER 3, 2016 SUNDAY, DECEMBER 4, 2016 08:00 – 17:00 Schubert 1 -4, Level One 08:00 – 11:00 Stolz 2 Workshop: WS01 - Young Investigator Research WS04 - Mesothelioma Workshop (TICKETED SESSION: 25€) Chair: Michele Carbone, USA and Communication Training (BY APPLICATION AND INVITATION ONLY) 08:00 – 11:45 Stolz 1 The workshop will address how to structure and deliver effec- JCSE01 - Joint IASLC-Chinese Society for Clinical tive presentations on clinical research, and how to deal with Oncology – Chinese Alliance Against Lung Cancer resulting questions effectively. The workshop will comprise Session two teaching lectures by a lead coach. These will be entertain- ing and will simultaneously teach and illustrate the principles CONTINENTAL BREAKFAST PROVIDED under discussion. After each lecture participants will break into groups to engage in interactive practical exercises. Every delegate will be expected to participate, including giving a presentation.WORKSHOP, HANDS-ON TRAINING 08:00 – 11:45 Strauss 2 AND SPECIAL SESSIONS 09:00 – 18:00 Strauss 1 Workshop: WS03 - IASLC Meets ESTI: Imaging in Lung Cancer Staging and Diagnosis Workshop: WS02 - IASLC Supporting the Implementation of Global CT Screening Track: Radiology/Staging/Screening (TICKETED SESSION: SOLD OUT) 08:00 – 11:45 Hall C8 Track: Radiology/Staging/Screening Young Investigator Session: THE CT SCREENING WORKSHOP REGISTRATION YI01a Clinical Trials & Scientific Mentoring COST INCLUDES: BUFFET LUNCH & DINNER Clinical Trials: Design, Publication & Interpretation CONTINENTAL BREAKFAST PROVIDED CPD ACCREDITED WORKSHOP (6 POINTS) 08:00 – 12:00 Schubert 4, Level One Objectives: Workshop: WS05 - International Society of Nurses in 1. This IASLC SSAC Workshop will provide an overview Cancer Care (ISNCC) & Bristol-Myers Squibb of the recent advances in lung cancer screening. Foundation Collaborative Workshop (SIGN UP REQUIRED) 2. To provide a forum to discuss the pertinent issues around implementation, which will impact on all health services as they move towards implementation. 3. What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer. 4. The consensus from this workshop will be published. 18:00 Networking Dinner How to Develop a Comprehensive System of Care for Lung Cancer Patients82 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

08:00 – 13:00 Strauss 1, Level One TUESDAY, DECEMBER 6 Hands-On Training Session: 10:25 – 10:55 Exhibit Showcase Theater Management of Lung Cancer Patients Through Innova- tive Laboratory Testing Across the Clinical Continuum Exhibit Showcase Session: Boehringer Ingelheim Giotrif: 10 Reasons to Use Afatinib in Lung Cancer Vargatef: Providing Benefits Even Where you May Not Expect It 10:30 – 11:45 Schubert 1, Level One Press Conference 10:30 – 11:45 Schubert 1, Level One 13:30 – 18:30 Schubert 2, Level One Press Conference International Thoracic Oncology Nursing Forum 14:30 – 15:00 Schubert 2, Level One WORKSHOP, HANDS-ON TRAINING (ITONF) (TICKETED SESSION: 25€) AND SPECIAL SESSIONS IASLC Business Meeting Chair: Glenda Colburn, Australia LIGHT REFRESHMENTS PROVIDED INCLUDING AWARD PRESENTATIONS AND UPDATES ON IASLC ACTIVITIES, FUTURE MEETINGS, ETC.MONDAY, DECEMBER 5 WEDNESDAY, DECEMBER 7 10:25 – 10:55 Exhibit Showcase Theater Exhibit Showcase Session: Roche Tissue Diagnostics 10:25 – 10:55 Exhibit Showcase Theater When H&E is not enough: Immunostaining & biomarker trends Exhibit Showcase Session: Otsuka Pharmaceutical and EQA surveillance in lung cancer diagnostics Relevance and management of hyponatremia in lung cancer – Modern approaches to staining lung biopsy samples and current current perspectives EQA data on ALK and PD-L1 . Hyponatremia is the most frequent electrolyte and body fluid balance 10:30 – 11:45 Schubert 1, Level One disturbance encountered in hospital clinical practice1. It is considered Press Conference an unfavorable prognostic factor in patients with cancer and differential diagnosis is challenging2,3. The objective of the “Exhibit Showcase Session” by Prim. Assoc. Prof. Doz. Dr. Marcus Säemann, Wilhelminenspital Wien, Austria is to discuss current challenges in the diagnosis and treatment of patients with hyponatremia, with emphasis on aspects of cancer patients . 10:30 – 11:45 Schubert 1, Level One Press Conference WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 83

INDUSTRY SUPPORTED SYMPOSIA SUNDAY, DECEMBER 4 12:45 – 14:15 SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB: 12:00 – 13:30 SYMPOSIUM SUPPORTED BY ARIAD PHARMACEUTICALS INC.: Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments Current and Emerging Treatments for HALL D (PLENARY HALL) Patients with ALK+ NSCLC STRAUSS 3 17:45 – 19:15 SYMPOSIUM SUPPORTED BY PRIME ONCOLOGY: Reaching New Heights in the 13:45 – 15:15 SYMPOSIUM SUPPORTED BY PFIZER ONCOLOGY: Management of Non-Small Cell Lung Cancer: Focus in EGFR-Targeted Therapy ALK and ROS1 in NSCLC: Optimising The Continuum of Care A prIME Oncology satellite symposium supported LEHAR 3–4 by Boehringer Ingelheim Pharma GmbH & Co. KG. HALL C7 15:30 – 17:00 SYMPOSIUM SUPPORTED BY TUESDAY, DECEMBER 6 MERCK-PFIZER ALLIANCE: 07:30 – 08:30 SYMPOSIUM SUPPORTED BY ABBVIE: Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Targeted Therapy on the Horizon for SCLC Receptor as a Target for Monotherapy LEHAR 3–4 and in Combination HALL C2INDUSTRY-SUPPORTED SYMPOSIA 17:15 - 18:45 SYMPOSIUM SUPPORTED BY ELI LILLY 12:45 – 14:15 SYMPOSIUM SUPPORTED BY NOVARTIS: AND COMPANY: Novel Treatment Strategies for ALK+ NSCLC: From Evidence to Practice Treatment Selection Strategies in LEHAR 3–4 Advanced NSCLC – A Symphony of Views 17:45 – 17:15 SYMPOSIUM SUPPORTED BY ROCHE: HALL C1 Harnessing The Power of MONDAY, DECEMBER 5 Immunotherapy and Targeted Therapy: Translating Evidence Into Practice HALL C2 07:30 – 08:30 SYMPOSIUM SUPPORTED BY ELI LILLY WEDNESDAY, DECEMBER 7 AND COMPANY: 12:45 – 14:15 SYMPOSIUM SUPPORTED BY MSD ONCOLOGY: Orchestrating Progress for Patients with Squamous Cell Lung Cancer Immuno-Oncology: A Renaissance in the STRAUSS 2 Treatment of Lung Cancer LEHAR 3–4 07:30 – 08:30 SYMPOSIUM SUPPORTED BY PEERVOICE: The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC STOLZ 2 84 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG

PLENARY SESSIONSSUNDAY, DECEMBER 4 TUESDAY, DECEMBER 619:00 – 20:45 OPENING PLENARY SESSION (PL01) 08:35 – 10:25 PLENARY SESSION (PL03): HALL D (PLENARY HALL) PRESIDENTIAL SYMPOSIUMWelcome Address HALL D (PLENARY HALL)Robert Pirker, Austria, Conference President CHAIRS: DAVID CARBONE, USA & ROBERT PIRKER, AUSTRIAWelcome AddressDavid Carbone, USA, IASLC President Presidential Address - David Carbone, USADistinguished Award Winner Presentations Lung Cancer Staging – Changing the Clinical PracticeFred Hirsch, USA, IASLC CEO Ramon Rami-Porta, SpainPerformance by the Vienna Boys Choir Top 4 Rated Abstracts with Discussants Tetsuya Mitsudomi, Japan, Jacek Jassem, Poland, Fiona Blakhall,Keynote Lecture: Is Smoking a Sole Factor in UK & David R. Gandara, USALung Cancer Development?Harald zur Hausen, Nobel Laureate, GermanyPerformance by the Vienna Boys Choir WEDNESDAY, DECEMBER 7 08:35 – 09:40 PLENARY SESSION (PL04A): IMMUNE CHECKPOINT INHIBITORS IN MONDAY, DECEMBER 5 ADVANCED NSCLC HALL D (PLENARY HALL)08:45 – 09:00 DISTINGUISHED LECTURE (PL02A) CHAIRS: JEAN-CHARLES SORIA, FRANCE & CAICUN ZHOU, CHINA Top 4 Immunotherapy Abstracts with Discussant HALL D (PLENARY HALL) Michael Boyer, AustraliaCHAIRS: ROBERT PIRKER, AUSTRIA, DAVID CARBONE, USA& FRED HIRSCH, USAWelcome Address 09:45 – 10:15 PLENARY KEYNOTE LECTURE (PL04B)Heinz Fischer, Former Federal President of the Republic of Austria(2004-2016) HALL D (PLENARY HALL)09:00 – 10:20 PLENARY SESSION (PL02B): CHAIRS: FRED HIRSCH, USA & ROBERT PIRKER, AUSTRIA PLENARY SESSIONS TOBACCO CONTROL The Role of Doctors in a Globalized World Alfred Gusenbauer, Former Federal Chancellor of the Republic of Austria HALL D (PLENARY HALL)CHAIRS: CAROLYN DRESLER, USA & PETER GOLDSTRAW, UK 16:00 – 18:00 CLOSING PLENARY SESSION (PL05):Implementing Tobacco Control Measures in Uruguay A LIFE IN THORACIC ONCOLOGY -Tabaré Vázquez, President of Uruguay REFLECTIONS FROM GIANTS ONFramework Convention on Tobacco Control: MILESTONES IN THE TREATMENT Its impact on Global Health ADVANCES IN LUNG CANCER Vera da Costa e Silva, SwitzerlandFree Trade & Investment Agreement Threatens Public Health HALL D (PLENARY HALL)Zarihah Zain, MalaysiaTobacco Control CHAIRS: PAUL BUNN, JR., USA & TONY MOK, HONG KONGLuke Clancy, Ireland Pathology - Adi Gazdar, USA Surgery - Peter Goldstraw, UK Radio-Oncology - David Ball, Australia Translational Lung Cancer Research - Nagahiro Saijo, Japan Chemotherapy - Thierry Le Chevalier, France Targeted Therapy - Frances Shepherd, Canada A Wise Man’s Conclusion - Lawrence Einhorn, USA Welcome to Yokohama for WCLC 2017 - Hisao Asamura, Japan Farewell - Robert Pirker, Austria WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 85

NETWORKING OPPORTUNITIES MONDAY, DECEMBER 5 – WEDNESDAY, DECEMBER 7 HALL B (EXHIBIT HALL) 09:30 – 16:30 Join peers, colleagues, sponsors and exhibitors in the Exhibit Hall (Hall B) for a variety of networking opportu- nities from Monday to Wednesday.NETWORKING OPPORTUNITIES SUNDAY, DECEMBER 4 THERE ARE MANY REASONS TO VISIT THE EXHIBIT HALL:  Check out the Poster Sessions with more than 500 posters WELCOME RECEPTION each day. Different sets of posters will be displayed each day Inclusive with full Conference and presenters will be present at their poster board from and Accompanying Person Registration. 14:15 – 15:45.  Interact with exhibiting companies on the show floor and After the Opening Plenary Session, delegates will move learn more about their newest products. into Hall B (Exhibit Hall) for the Welcome Reception  Get a jump start on the day with a hot cup of barista coffee with local wines and canapés, allowing you the oppor- right before diving into the educational sessions! tunity to mix and mingle with colleagues, friends and  Take a break and recharge before a busy afternoon while exhibitors. enjoying a free light lunch in the Exhibit Hall.  If you are a coffee addict – check out the barista stations on the exhibit floor providing a variety of hot espresso beverages free of charge during exhibit hours.  Reconnect with fellow colleagues.  Take time to check your email at one of the internet stations.  Charge your mobile devices or laptops at one of the charging stations.  Enjoy a meal in the Exhibit Hall Restaurant.  Take the opportunity to unwind from sessions. Sit down with clients, friends or colleagues at one of the many seating spots in the exhibit hall. Welcome Reception 20:45 – 21:45 WEDNESDAY, DECEMBER 7 HALL B (EXHIBIT HALL) WCLC 2016 TOGETHER AGAINST LUNG CANCER SUPPORTED BY 19:00 – 23:00 Join us in the fight against lung cancer for an evening dinner at the Hofburg Vienna. 86 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG























07:30 – 08:30 ISS06: The Changing Treatment 09:45 PL02b.03: Free Trade & Investment Agreement Paradigm After Progression in Advanced Threatens Public Health EGFR–Mutated NSCLC Zarihah Zain, Lincoln University College Malaysia, – PeerVoice Malaysia TRACK: INDUSTRY SUPPORTED SYMPOSIUM 10:00 PL02b.04: Tobacco Control Luke Clancy, TobaccoFree Research Institute Ireland, ROOM: STOLZ 2 Ireland CHAIR: JAMES YANG (MODERATOR), NATIONAL TAIWAN UNIVERSITY AND NTU CANCER CENTER, TAIWAN 07:30 ISS06.01: Introduction: The Path Forward in Advanced EGFR–Mutated NSCLC James Yang (Moderator), National Taiwan University 10:25 – 11:00 NETWORKING OPPORTUNITY & and NTU Cancer Center, Taiwan POSTER PRESENTERS PRESENT FOR P1 POSTERS 07:35 ISS06.02: Emerging Algorithm for Advanced EGFR–Mutated NSCLC After Progression Hall B (Exhibit Hall) Anders Mellemgaard, Herlev University Hospital, Refreshments provided Denmark 07:45 ISS06.03: Best Practices for Managing Advanced EGFR–Mutated NSCLC After Progression Howard West, Swedish Cancer Institute, USA 07:55 ISS06.04: Panel Discussion: Overcoming Obstacles 10:30 – 11:45 PR02: Press Conference Managing Advanced EGFR–Mutated NSCLC After Progression ROOM: SCHUBERT 1, LEVEL ONE All Faculty For information on topics and speakers, please visit 08:15 ISS06.05: Conclusions & Questions the Press & Media page on the Conference website at James Yang (Moderator), National Taiwan University wclc2016.iaslc.org/press-media/press-media/ and NTU Cancer Center, TaiwanMONDAY  DECEMBER 5 08:45 – 09:00 PL02a: 11:00 – 12:30 ED01: Biology of Lung Cancer Distinguished LectureHALL D (PLENARY HALL) TRACK: BIOLOGY/PATHOLOGY ROOM: HALL D (PLENARY HALL) ROOM: HALL C1 CHAIRS: ROBERT PIRKER, AUSTRIA, DAVID CARBNE, USA CHAIRS: RAFAEL ROSELL, CATALAN INSTITUTE OF ONCOLOGY; & FRED HIRSCH, USA GERMANS TRIAS I PUJOL HEALTH SCIENCES INSTITUTE AND HOSPITAL, SPAIN & MARTIN FILIPITS, 09:00 PL02a.01: Heinz Fischer, Former Federal President MEDICAL UNIVERSITY OF VIENNA, AUSTRIA of the Republic of Austria (2004 – 2016) 11:00 ED01.01: Understanding Biology: The Road to Cure? David Carbone, The Ohio State Wexner Medical Center, USA 11:25 ED01.02: Tobacco Carcinogens and Lung Cancer Susceptibility Stephen Hecht, University of Minnesota, USA 11:50 ED01.03: Insights from TCGA Ramaswamy Govindan, Washington University School 09:00 – 10:20 PL02b: Tobacco Control of Medicine, USA TRACK: TOBACCO CONTROL ROOM: HALL D (PLENARY HALL) CHAIRS: CAROLYN DRESLER, CENTER FOR TOBACCO PRODUCTS USA FDA, USA 09:00 PL02b.01: Implementing Tobacco Control Measures in Uruguay President Dr. Tabaré Vázquez, Uruguay 09:25 PL02b.02: Framework Convention on Tobacco Control: Its impact on Global Health Vera Da Costa E Silva, WHO Framework Convention on Tobacco Control, Switzerland 98 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG